Press releases
ADVITECH’S DERMYLEX ENTERS THE AUSTRIAN MARKET
11 June 2009
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - June 11, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) today announces the execution of an exclusive agreement with Pelpharma Handels GmbH ("Pelpharma") for the distribution of Dermylex® in Austria.
This agreement with Pelpharma is for an initial three-year term and may be renewed. It grants Pelpharma exclusivity for the Austrian market, and it includes minimum yearly commitment levels for the purchase of Dermylex®.
Austria has a population of over 8 million people and Pelpharma has a dedicated sales force network that reaches to over 600 dermatologists. Pelpharma's dedicated work force is, in the Corporation's opinion, strategically positioned to penetrate the dermatologists and paediatricians market. Pelpharma is totally focused on dermatological issues that incorporate the complete coverage of the Austrian market. "We are very happy to be represented by Pelpharma which, we believe, has the capacity to successfully market Dermylex® in Austria" said Renaud Beauchesne, Executive Chairman at Advitech.
"The market of dietary supplements having special medical purpose is an interesting market, not only in Austria, but in Europe as well. The addition of Dermylex® to the existing Pelpharma portfolio is an excellent opportunity for us to enter this marketplace and create new revenues" said Nicki Peljak, President at Pelpharma.
ABOUT PELPHARMA HANDELS GmbH www.pelpharma.at:
Pelpharma is a 100% privately owned pharmaceutical company operating in Austrian dermatology markets. Its owner has more than 20 years of experience in dermatology, the sole focus of Pelpharma. The major part of the company´s sales is achieved with dermatological drugs needing prescription. The product portfolio consists partly of generic products where Pelpharma is the holder of registration and partly of in-licensed products from companies who do not have their own distribution in Austria.
ABOUT ADVITECH INC. www.advitech.com:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Advitech produces Dermylex® for the treatment of mild-to-moderate psoriasis.
Advitech has initiated an innovative wound healing research program to develop new applications for both its XP-828L and IM technological platforms.
-30-
This press release contains forward-looking statements, which reflect the Corporation's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Advitech Inc.
Renaud Beauchesne, MBA | Serge Comeau |
Executive Chairman | Investor's relations |
418-686-7498, ext. 228 | 514-862-4160 |